August 2019

Contents

Editorial

• HTB 23 August 2019 online: second reports from IAS 2019

Special reports

• Fit for purpose: antiretroviral treatment optimisation

Conference reports

• 10th IAS Conference on HIV Science (IAS 2019) in Mexico City

• Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution

• Switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance

• Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study

• Dolutegravir for younger children: results from the ODYSSEY trial

• PK advantages of TAF/FTC over TDF/FTC for HIV PrEP might compensate for low adherence: sub-analysis of DISCOVER study

Antiretrovirals

• Cabotegravir/rilpivirine long-acting injectable HIV drugs submitted to EMA

PDFs

• 23 August 2019 vol 20 no 10